Jasper Therapeutics Stock Beta
| JSPR Stock | USD 2.90 0.06 2.03% |
Fundamental analysis of Jasper Therapeutics allows traders to better anticipate movements in Jasper Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Jasper | Beta | Build AI portfolio with Jasper Stock |
Jasper Therapeutics Company Beta Analysis
Jasper Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Jasper Therapeutics Beta | 2.7 |
Most of Jasper Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jasper Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Jasper Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Jasper Therapeutics is extremely important. It helps to project a fair market value of Jasper Stock properly, considering its historical fundamentals such as Beta. Since Jasper Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Jasper Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Jasper Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Jasper Therapeutics has a Beta of 2.697. This is 213.6% higher than that of the Biotechnology sector and 94.03% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Jasper Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jasper Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jasper Therapeutics could also be used in its relative valuation, which is a method of valuing Jasper Therapeutics by comparing valuation metrics of similar companies.Jasper Therapeutics is currently under evaluation in beta category among its peers.
Jasper Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Jasper Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Jasper Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Jasper Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Jasper Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Jasper Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Jasper Therapeutics' value.| Shares | Ubs Group Ag | 2025-03-31 | 534.6 K | Kingdon Capital Management Llc | 2025-03-31 | 490 K | Citadel Advisors Llc | 2025-03-31 | 375.2 K | Bank Of America Corp | 2025-03-31 | 360.7 K | Geode Capital Management, Llc | 2025-03-31 | 263.7 K | Goldman Sachs Group Inc | 2025-03-31 | 233.8 K | State Street Corp | 2025-03-31 | 227.9 K | Deutsche Bank Ag | 2025-03-31 | 169.3 K | Lion Point Capital, Lp | 2025-03-31 | 146.5 K | Soleus Capital Management, L.p. | 2025-03-31 | 1.5 M | Velan Capital Investment Management Lp | 2025-03-31 | 1.4 M |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Jasper Therapeutics will likely underperform.
Jasper Fundamentals
| Return On Equity | -1.01 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | (1.74 M) | ||||
| Shares Outstanding | 15.02 M | ||||
| Shares Owned By Insiders | 1.27 % | ||||
| Shares Owned By Institutions | 89.72 % | ||||
| Number Of Shares Shorted | 1.36 M | ||||
| Price To Book | 1.05 X | ||||
| EBITDA | (71.39 M) | ||||
| Net Income | (71.27 M) | ||||
| Cash And Equivalents | 60.81 M | ||||
| Cash Per Share | 1.60 X | ||||
| Total Debt | 1.81 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 9.56 X | ||||
| Book Value Per Share | 2.81 X | ||||
| Cash Flow From Operations | (62.6 M) | ||||
| Short Ratio | 0.93 X | ||||
| Earnings Per Share | (5.27) X | ||||
| Target Price | 20.13 | ||||
| Number Of Employees | 64 | ||||
| Beta | 2.7 | ||||
| Market Capitalization | 44.47 M | ||||
| Total Asset | 79.9 M | ||||
| Retained Earnings | (240.87 M) | ||||
| Working Capital | 60.57 M | ||||
| Net Asset | 79.9 M |
About Jasper Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jasper Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jasper Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jasper Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.